Advertisement

Metabolomics

, 15:4 | Cite as

Towards quality assurance and quality control in untargeted metabolomics studies

  • Richard D. BegerEmail author
  • Warwick B. DunnEmail author
  • Abbas Bandukwala
  • Bianca Bethan
  • David Broadhurst
  • Clary B. Clish
  • Surendra Dasari
  • Leslie Derr
  • Annie Evans
  • Steve Fischer
  • Thomas Flynn
  • Thomas Hartung
  • David Herrington
  • Richard Higashi
  • Ping-Ching Hsu
  • Christina Jones
  • Maureen Kachman
  • Helen Karuso
  • Gary Kruppa
  • Katrice Lippa
  • Padma Maruvada
  • Jonathan Mosley
  • Ioanna Ntai
  • Claire O’Donovan
  • Mary Playdon
  • Daniel Raftery
  • Daniel Shaughnessy
  • Amanda Souza
  • Timothy Spaeder
  • Barbara Spalholz
  • Fariba Tayyari
  • Baljit Ubhi
  • Mukesh Verma
  • Tilman Walk
  • Ian Wilson
  • Keren Witkin
  • Daniel W. Bearden
  • Krista A. ZanettiEmail author
Short Communication

Abstract

We describe here the agreed upon first development steps and priority objectives of a community engagement effort to address current challenges in quality assurance (QA) and quality control (QC) in untargeted metabolomic studies. This has included (1) a QA and QC questionnaire responded to by the metabolomics community in 2015 which recommended education of the metabolomics community, development of appropriate standard reference materials and providing incentives for laboratories to apply QA and QC; (2) a 2-day ‘Think Tank on Quality Assurance and Quality Control for Untargeted Metabolomic Studies’ held at the National Cancer Institute’s Shady Grove Campus and (3) establishment of the Metabolomics Quality Assurance and Quality Control Consortium (mQACC) to drive forward developments in a coordinated manner.

Keywords

Quality assurance (QA) Quality control (QC) Community engagement Test materials Reporting metrics 

Notes

Author contributions

All authors contributed equally to the preparation of this manuscript.

Compliance with ethical standards

Conflict of interest

There are no conflicts of interest to disclose. The authors declare no competing financial interests. The views presented here do not necessarily reflect those of the U.S. Food and Drug Administration. Views expressed in this article are those of the authors and do not necessarily represent views or policies of the US EPA. Mention of products or trade names does not indicate endorsement of by the US EPA. Any use of trade, firm, or product names is for descriptive purposes only and does not imply endorsement by the U.S. Government.

Research involving human and animal participants

No research involving human or animal participants is included.

Informed consent

No research involving human participants is included and no informed consent was therefore collected.

References

  1. Bouhifd, M., Beger, R., Flynn, T., Guo, L., Harris, G., Hogberg, H., Kaddurah-Daouk, R., Kamp, H., Kleensang, A., Maertens, A., & Odwin-DaCosta, S. (2015). t4 Workshop Report: Quality Assurance of Metabolomics. Altex, 32(4), 319.CrossRefGoogle Scholar
  2. Bowden, J. A., Heckert, A., Ulmer, C. Z., Jones, C. M., Koelmel, J. P., Abdullah, L., et al. (2017). Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using standard reference material 1950 metabolites in frozen human plasma. Journal of Lipid Research, 58(12), 2275–2288.CrossRefGoogle Scholar
  3. Davies, S. K., Ang, J. E., Revell, V. L., Holmes, B., Mann, A., Robertson, F. P., et al. (2014). Effect of sleep deprivation on the human metabolome. Proceedings of the National Academy of Sciences, 111(29), 10761–10766.CrossRefGoogle Scholar
  4. Drenos, F., Davey Smith, G., Ala-Korpela, M., Kettunen, J., Würtz, P., Soininen, P., et al. (2016). Metabolic characterization of a rare genetic variation within APOC3 and its lipoprotein lipase–independent effects. Circulation: Genomic and Precision Medicine, 9(3), 231–239.Google Scholar
  5. Dunn, W. B., Broadhurst, D. I., Edison, A., Guillou, C., Viant, M. R., Bearden, D. W., et al. (2017). Quality assurance and quality control processes: summary of a metabolomics community questionnaire. Metabolomics, 13(5), 50.CrossRefGoogle Scholar
  6. Food and Drug Administration (FDA). (2001) Guidance for industry: Bioanalytical method validation. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and ResearchGoogle Scholar
  7. ISO 9000. (2015). Quality management systems—Fundamentals and vocabulary, Geneva: ISO.Google Scholar
  8. Kaddurah-Daouk, R., & Weinshilboum, R. (2015). Metabolomic signatures for drug response phenotypes: Pharmacometabolomics enables precision medicine. Clinical Pharmacology & Therapeutics, 98(1), 71–75.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Richard D. Beger
    • 1
    Email author
  • Warwick B. Dunn
    • 2
    Email author
  • Abbas Bandukwala
    • 3
  • Bianca Bethan
    • 4
  • David Broadhurst
    • 5
  • Clary B. Clish
    • 6
  • Surendra Dasari
    • 7
  • Leslie Derr
    • 8
  • Annie Evans
    • 9
  • Steve Fischer
    • 10
  • Thomas Flynn
    • 3
  • Thomas Hartung
    • 11
  • David Herrington
    • 12
  • Richard Higashi
    • 13
  • Ping-Ching Hsu
    • 14
  • Christina Jones
    • 15
  • Maureen Kachman
    • 16
  • Helen Karuso
    • 17
  • Gary Kruppa
    • 18
  • Katrice Lippa
    • 15
  • Padma Maruvada
    • 19
  • Jonathan Mosley
    • 20
  • Ioanna Ntai
    • 21
  • Claire O’Donovan
    • 22
  • Mary Playdon
    • 23
  • Daniel Raftery
    • 24
  • Daniel Shaughnessy
    • 25
  • Amanda Souza
    • 21
  • Timothy Spaeder
    • 9
  • Barbara Spalholz
    • 23
  • Fariba Tayyari
    • 26
  • Baljit Ubhi
    • 27
  • Mukesh Verma
    • 23
  • Tilman Walk
    • 4
  • Ian Wilson
    • 28
  • Keren Witkin
    • 23
  • Daniel W. Bearden
    • 29
    • 30
  • Krista A. Zanetti
    • 23
    Email author
  1. 1.National Center for Toxicological Research, US Food and Drug AdministrationJeffersonUSA
  2. 2.School of Biosciences, Phenome Centre Birmingham and Institute for Metabolism and Systems ResearchUniversity of BirminghamBirminghamUK
  3. 3.Food and Drug AdministrationSilver SpringUSA
  4. 4.Metanomics Health GmBHBerlinGermany
  5. 5.Edith Cowan UniversityPerthAustralia
  6. 6.Broad Institute of MIT and HarvardCambridgeUSA
  7. 7.Mayo ClinicRochesterUSA
  8. 8.Office of the DirectorNational Institutes of HealthBethesdaUSA
  9. 9.MetabolonResearch Triangle ParkUSA
  10. 10.Agilent TechnologiesSanta ClaraUSA
  11. 11.Johns Hopkins School of Public HealthBaltimoreUSA
  12. 12.Wake Forest UniversityWinston-SalemUSA
  13. 13.University of KentuckyLexingtonUSA
  14. 14.University of Arkansas Medical SciencesLittle RockUSA
  15. 15.National Institute of Standards and TechnologyGaithersburgUSA
  16. 16.University of MichiganAnn ArborUSA
  17. 17.Biocrates Inc.InnsbruckAustria
  18. 18.Bruker DaltronicsBillericaUSA
  19. 19.National Institute of Diabetes and Digestive and Kidney DisordersBethesdaUSA
  20. 20.National Exposure Research LaboratoryUS Environmental Protection AgencyAthensUSA
  21. 21.Thermo Fisher ScientificSan JoseUSA
  22. 22.European Molecular Biology Laboratory -European Bioinformatics InstituteHinxtonUK
  23. 23.National Cancer InstituteRockvilleUSA
  24. 24.University of WashingtonSeattleUSA
  25. 25.National Institute of Environmental HealthDurhamUSA
  26. 26.University of GeorgiaAthensUSA
  27. 27.AB SciexFraminghamUSA
  28. 28.Imperial College LondonLondonUK
  29. 29.National Institute of Standards and TechnologyCharlestonUSA
  30. 30.Ichthus Unlimited, LLCWest Des MoinesUSA

Personalised recommendations